Infected Blood Compensation Scheme

Lindsay Hoyle Excerpts

Tuesday 14th April 2026 Commons Chamber

[The Paymaster General and Minister for the Cabinet Office (Nick Thomas-Symonds)]

With permission, I will update the House on the Government’s response to the recommendations of the infected blood inquiry’s additional report.

I will start by updating the House on the delivery of compensation by the Infected Blood Compensation Authority—or IBCA, as we refer to it. As of 7 April, 3,273 people have received an offer and over £2 billion has now been paid out. That includes the first payments to all eligible groups. I am sure that Members across the whole House will welcome that progress.

In July last year, the infected blood inquiry published its additional report, which made recommendations for both the Government and IBCA. Part of our response to that report was a public consultation on changes to the infected blood compensation scheme. I am here today to update the House on the outcome of that consultation. First, I should say that I am deeply grateful to everyone who responded and provided deeply personal stories. They must be at the heart of the decisions that the Government make, just as they were throughout the work of the inquiry.

The consultation was vital for engaging the community on our proposals. The Government have also sought advice from the infected blood compensation scheme technical expert group. Alongside the consultation response, today I am publishing the group’s final report, which sets out its advice to the Government and amendments to the compensation scheme. To inform that advice, the technical expert group conducted roundtable discussions with community representatives on specific aspects of the scheme, and that was separate to the consultation. For transparency, I am also publishing the minutes of the roundtable discussions, the group’s own meetings and a summary of written responses to the roundtables.

Let me turn to the changes to the scheme. Today the Government have published our full response to the consultation, and that sets out how the scheme will now change. Before I lay out each change in detail, let me explain the overall package. The community was clear that the scheme must do more to recognise people’s individual experiences and compensate them fairly in a way that minimises the administrative burden placed on those who have been harmed, minimises the demand for evidence and maintains the delivery of tariff-based compensation. Those requirements underpin the changes.

For infected people, the changes will increase the amount of core compensation available and increase the options available for supplementary compensation awards. For affected people, additional core compensation will be available to those eligible. We consulted on seven specific areas, and we are making substantive changes in all seven. In four areas, we are actually going further than our original proposal.

Let me turn first to the special category mechanism. We will introduce a new supplementary award to give additional compensation to people who have been assessed as eligible for the SCM or who can now demonstrate to IBCA that they meet the criteria. After considering the community’s views, we will ensure that every eligible person has this award backdated to 2017, because that is when the special category mechanism was first introduced.

Many of those infected suffered from terrible mental health issues as a result of their infection, as we heard in their testimonies. We will amend the scheme so that the new SCM supplementary award gives people additional compensation where the psychological harm that they experienced means that the core route compensation simply does not go far enough. We believe that this will result in more comprehensive recognition of the mental health issues caused by infected blood and the resulting years of harm.

The inquiry recommended that we change the core route’s severity bandings to recognise the harms caused to infected people by interferon treatment, and proposed a new “level 2B” severity banding for those who receive this treatment. We accept that change is necessary, and we will introduce this new severity band to increase people’s injury, financial loss and care awards. In addition, if someone has had multiple rounds of interferon treatment, they will be compensated for each round.

The inquiry recommended changes to the calculation of past financial loss and past care awards for those who choose to continue receiving support scheme payments. We will remove the 25% deduction applied to past care compensation, as was recommended by the inquiry. The consultation also set out two options for how financial loss could be calculated for those who continue to receive support scheme payments: the way the scheme currently does it, and an alternative. Because of the range of views on which was best, we will ensure that people receive past financial loss compensation based on whichever of the two calculations presented is most financially beneficial for them.

The inquiry asked the Government to look at the evidence requirements for the exceptional loss award. We were keen to hear the community’s views on that in order to develop a way forward that avoided lengthy, individualised assessments of people’s circumstances. We will ensure that all forms of evidence of actual earnings can be considered by IBCA. We will also make additional compensation available to infected people who lack evidence of earnings but who had clear potential to earn more than average. We will offer a £60,000 lump sum on top of people’s core awards to those who can show they either had a job offer or recently started a job where the salary was higher than the median salary but had their progress impeded by their infection.

Through the consultation, we also heard about the experiences of affected people and the particular harms they suffered. We will increase the core injury award for several groups of affected people, including bereaved parents whose child sadly died before they turned 18, bereaved partners, and children and siblings affected under the age of 18. Those changes will give more compensation to affected people whose particular experience of the scandal was undoubtedly profound and deeply harmful. The awards will form part of the core award, and they will not require additional evidence from applicants.

I know that the matter of unethical research is of particular concern to Members across the House. It is one of the most shocking aspects of the scandal. We heard that the existing approach may not have compensated everyone who suffered that wrongdoing. We have therefore changed the scope of the award so that anyone treated in the UK for a bleeding disorder in 1985 or earlier will receive further compensation.

It was also clear from the consultation responses that the amount offered does not reflect the harm done. I say today to the House that we will increase the unethical research awards. That includes increasing the £25,000 for those who attended Treloar’s school to £60,000 as well as introducing a new unethical research award for those treated elsewhere for a bleeding disorder during childhood at a rate of £45,000. We are also tripling the award for those treated for a bleeding disorder in adulthood to £30,000. I have touched on all seven of the areas we directly addressed in the consultation; of course, I encourage hon. Members across the House to read the full response that is being published.

The consultation also invited respondents to raise any other concerns they had about the design of the scheme. One of the most compelling things we heard was that the scheme does not sufficiently recognise the profound impact of infection during childhood. We have heard the community clearly on that, so we will make a further change to the compensation scheme to address it: we will introduce a 50% increase to the core autonomy award for people who were infected at age 18 or under.

I hope those changes go some way to showing our commitment to listening to the community and making decisions, with those impacted at the forefront of our minds. In order to make those substantial changes to the scheme, we will bring forward further legislation in due course.

While the consultation provided one way for the community to offer feedback, the inquiry recommended there be an identified way for concerns to be considered. Today, I am pleased to launch a new mechanism that builds on existing engagement and feedback channels through which people can raise concerns about the function of the infected blood compensation scheme with the Cabinet Office and with IBCA. Both organisations will then publish quarterly summaries of feedback received on the scheme’s design and delivery, and any action being taken as a result. I expect the first of those summaries to be published in early July.

The findings of the inquiry must be met with tangible, systemic change. I hope that what I have set out goes some way towards showing our commitment to enacting this change. I pay tribute to Sir Brian Langstaff, his team and everyone who gave testimony to the inquiry for ensuring that that human element of this tragedy remains a focal point of the inquiry’s work.

The compensation scheme’s most basic purpose is to provide financial recognition of the losses and harms faced by victims, both infected and affected. Beyond that, it must reflect and embody their stories if it is to truly deliver justice, not just for those we tragically lost, but for those who continue to fight. I commend this statement to the House.

[Mr Speaker]

I call the shadow Minister.